Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUMINA: DE-109 in Uveitis
NCT03711929Phase 3Terminated
- Sponsor
- Santen Pharmaceutical
- Start
- Nov 2018
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of sirolimus in non-infectious posterior uveitis (NIPU) (4 arms), sponsored by Santen Pharmaceutical. Primary endpoint: Vitreous Haze (VH) of Zero Response at Month 5. Started Nov 2018; status: terminated.
02
Drugs
sirolimus
03
Conditions
non-infectious posterior uveitis (NIPU)
Beyond the preview
Go deeper on NCT03711929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03711929.